news...nc, page-2

re: news...ann. posted PHARMAXIS SIGNS FIRST DISTRIBUTOR FOR ARIDOL
Specialist pharmaceutical company Pharmaxis Ltd (ASX:PXS, NASDAQ:PXSL) announced
today that a distribution agreement for its first product, Aridol™, has been signed. The
agreement, with Nigaard Pharma AS, covers the distribution and marketing of Aridol, an
asthma management tool, throughout the Scandinavian countries.
Nigaard Pharma AS is a specialist respiratory pharmaceutical company based in Oslo,
Norway and with offices in Sweden, Denmark and Finland. It has an existing network of
contacts with pulmonary specialists and respiratory laboratories which will be invaluable for
developing the market for Aridol. The five-year agreement is effective immediately, and will
capitalise on Pharmaxis’ earlier Scandinavian marketing and pre-registration activities for
Aridol.
Alan Robertson, Pharmaxis chief executive officer said: ‘This is the first of our global
marketing and distribution agreements for Aridol and is an exciting milestone for
Pharmaxis. We expect Sweden will be the first European country to approve Aridol and
have selected Nigaard Pharma for their established networks, excellent local knowledge
and the dedicated resources they can commit to make Aridol a success.’
Kjetil Herland, Nigaard managing director said: ‘Aridol is an exciting innovation in asthma
management and is eagerly anticipated by the Nordic respiratory specialists. Aridol
represents a significant commercial opportunity for Nigaard Pharma and we look forward to
working closely with Pharmaxis.’
Pharmaxis lodged its application for regulatory and marketing approval of Aridol with the
Swedish Medical Products Agency (MPA) in May 2005, and anticipates registration for
Aridol in the first-half of 2006. Aridol is designed to identify patients with active airway
inflammation such as occurs in asthma, provide information on the severity of their disease,
and help monitor the effectiveness of their current treatment. Asthma is a widespread and
chronic condition which has a major impact on public health in Scandinavia. Five percent
(1.25 million) of the Nordic population have clinical symptoms of asthma. Since the early
1980s, asthma rates have doubled in children and increased by 50 percent in adults.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au.
ends#
SOURCE: Pharmaxis Ltd, Sydney, Australia